{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(11)"],"submitter":["Ahmed AA"],"pubmed_abstract":["<h4>Objective</h4>This study assessed the anticancer and antimetastatic impact of rivaroxaban-ciprofloxacin mixture and explored its molecular mechanism by examining its ability to target the epithelial-mesenchymal transition (EMT) pathway.<h4>Methods</h4>Following incubation periods of 24 and 72 hours, HeLa and normal human fibroblast (NHF) cell lines were employed to investigate the anticancer and safety properties of rivaroxaban, ciprofloxacin, rivaroxaban-ciprofloxacin mixture, and carboplatin, with concentrations varying from 0.1 to 1000 µg/ml. The wound healing assay (WHA) of cervical cancer cells was employed to assess the anti-metastatic effects of the mixture at three time points: 0, 12, and 24 hours.. A combination index (CI) and selectivity toxicity index (SI) score were estimat"],"journal":["Asian Pacific journal of cancer prevention : APJCP"],"pagination":["4195-4207"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948181"],"repository":["biostudies-literature"],"pubmed_title":["Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway."],"pmcid":["PMC12948181"],"pubmed_authors":["Ahmed AA"],"additional_accession":[]},"is_claimable":false,"name":"Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.","description":"<h4>Objective</h4>This study assessed the anticancer and antimetastatic impact of rivaroxaban-ciprofloxacin mixture and explored its molecular mechanism by examining its ability to target the epithelial-mesenchymal transition (EMT) pathway.<h4>Methods</h4>Following incubation periods of 24 and 72 hours, HeLa and normal human fibroblast (NHF) cell lines were employed to investigate the anticancer and safety properties of rivaroxaban, ciprofloxacin, rivaroxaban-ciprofloxacin mixture, and carboplatin, with concentrations varying from 0.1 to 1000 µg/ml. The wound healing assay (WHA) of cervical cancer cells was employed to assess the anti-metastatic effects of the mixture at three time points: 0, 12, and 24 hours.. A combination index (CI) and selectivity toxicity index (SI) score were estimat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-07-16T22:24:56.968Z","creation":"2026-07-11T03:11:59.904Z"},"accession":"S-EPMC12948181","cross_references":{"pubmed":["41312948"],"doi":["10.31557/APJCP.2025.26.11.4195"]}}